SynthesisBMC public health2025
The burden of congenital heart disease in Malaysia: a comprehensive review and meta-analytic synthesis, 1970-2024.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCongenital heart disease (CHD) remains a leading contributor to congenital anomalies globally. In Malaysia, available data on CHD are limited, with birth prevalence estimates varying widely across studies, suggesting potential underestimation and gaps in understanding CHD prevalence. This systematic review and meta-analysis aimed to assess the reported prevalence and subtypes of CHD in Malaysia.
methodsThis study was conducted according to PRISMA guidelines and registered with PROSPERO (CRD42024500619). Studies from the Malaysian population published from inception till October 2024 were searched in Google Scholar, PubMed, EMBASE, and Web of Science.
resultsA total of 303 were identified and 7 studies met the inclusion criteria. Data on total CHD prevalence and 36 specific subtypes were collected and pooled using an inverse variance random-effect model. Among the 7 eligible studies, encompassing 1,474,172 live births, the pooled CHD prevalence was 4.21 per 1,000 live births (95% confidence interval [CI] [2.21–6.22]; P < 0.0001), with significant heterogeneity (I2 = 99%). The reported prevalence exhibited markedly variation, declining from 6.80 per live births (95%CI [5.19–8.41]) in 1963 to 1.35 per 1,000 live births (95%CI [0.96–1.74]) in 1999, before rising again to 6.80 per 1,000 live births (95%CI [6.63–6.97]) in 2020. Among CHD subtypes, ventricular septal defects were the most prevalent (36.23%), followed by patent ductus arteriosus (18.16%). Subgroup analyses by geographic location (states of Malaysia), publication year, and study design highlighted further variability in prevalence rates.
conclusionsThe observed fluctuations in CHD prevalence underscore the necessity for robust surveillance systems and investigation into the factors driving these trends in Malaysia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.